HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M300310-JLR200v1 45/5/831    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oestvang, J. Articles by Anthonsen, M. W. Search for Related Content PubMed PubMed Citation Articles by Oestvang, J. Articles by Anthonsen, M. W. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 45, 831-838, May 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Modification of LDL with human secretory phospholipase A₂ or sphingomyelinase promotes its arachidonic acid-releasing propensity

Janne Oestvang^*, Dominique Bonnefont-Rousselot, Ewa Ninio, Jukka K. Hakala^**, Berit Johansen^* and Marit W. Anthonsen^1,

^* Faculty of Natural Science and Technology, Norwegian University of Science and Technology, Trondheim, Norway
Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Laboratoire de Biochimie B, Groupe Hospitalier Pitié-Salpêtrière, and Institut Fédératif Coeur Muscle Vaisseaux, Paris, France
Institut National de la Santé et de la Recherche Médicale U525, Institut Fédératif Coeur Muscle Vaisseaux, and Université Pierre et Marie Curie, Paris, France
^** Wihuri Research Institute, Helsinki, Finland

¹ To whom correspondence should be addressed. e-mail: marit.w.anthonsen{at}medisin.ntnu.no

Oxidation and lipolytic remodeling of LDL are believed to stimulate LDL entrapment in the arterial wall, expanding the inflammatory response and promoting atherosclerosis. However, the cellular responses and molecular mechanisms underlying the atherogenic effects of lipolytically modified LDL are incompletely understood. Human THP-1 monocytes were prelabeled with [³H]arachidonic acid (AA) before incubation with LDL or LDL lipolytically modified by secretory PLA₂ (sPLA₂) or bacterial sphingomyelinase (SMase). LDL elicited rapid and dose-dependent extracellular release of AA in monocytes. Interestingly, LDL modified by sPLA₂ or SMase displayed a marked increase in AA mobilization relative to native LDL, and this increase correlated with enhanced activity of cytosolic PLA₂ (cPLA₂) assayed in vitro as well as increased monocyte tumor necrosis factor- secretion. The AA liberation was attenuated by inhibitors toward cPLA₂ and sPLA₂, indicating that both PLA₂ enzymes participate in LDL-induced AA release.

In conclusion, these results demonstrate that LDL lipolytically modified by sPLA₂ or SMase potentiates cellular AA release and cPLA₂ activation in human monocytes. From our results, we suggest novel atherogenic properties for LDL modified by sPLA₂ and SMase in AA release and signaling, which could contribute to the inflammatory gene expression observed in atherosclerosis.

Abbreviations: AA, arachidonic acid; BEL, bromoenol lactone; cPLA₂, cytosolic phospholipase A₂; iPLA₂, Ca²⁺-independent phospholipase A₂; LDL_nat, native LDL; MAFP, methyl arachidonyl fluorophosphonate; MDA, malondialdehyde equivalents; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OA, oleic acid; PLA₂, phospholipase A₂; SMase, sphingomyelinase; sPLA₂, secretory phospholipase A₂; TNF-, tumor necrosis factor-

Supplementary key words low density lipoprotein remodeling • inflammation • atherosclerosis • monocytes • oleic acid

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Preiss, D. Namgaladze, and B. Brune Critical role for classical PKC in activating Akt by phospholipase A2-modified LDL in monocytic cells Cardiovasc Res, March 1, 2007; 73(4): 833 - 840. [Abstract] [Full Text] [PDF]

				P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF]

				S. M. Boekholdt, T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J.P. Kastelein, C. E. Hack, et al. Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 839 - 846. [Abstract] [Full Text] [PDF]

				S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen, P. J. J. van Gorp, I. van der Made, B. Johansen, M. H. Hofker, and M. P. J. de Winther Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition J. Lipid Res., February 1, 2005; 46(2): 201 - 210. [Abstract] [Full Text] [PDF]